Jazz Pharmaceuticals plc Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Jazz Pharmaceuticals plc filed its quarterly 10-Q report for Q1 2024 on May 2, 2024.</b>

AI Summary

Jazz Pharmaceuticals plc (JAZZ) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Jazz Pharmaceuticals plc filed a 10-Q report for the quarter ended March 31, 2024. The filing covers the period from January 1, 2024, to March 31, 2024. The company's principal business is in Pharmaceutical Preparations (SIC 2834). Jazz Pharmaceuticals plc is incorporated in L2 with its fiscal year ending December 31. The filing was made on May 2, 2024.

Why It Matters

For investors and stakeholders tracking Jazz Pharmaceuticals plc, this filing contains several important signals. This 10-Q filing provides investors with the latest financial performance and operational updates for Jazz Pharmaceuticals plc for the first quarter of 2024. Understanding the details within this report is crucial for assessing the company's current financial health, strategic direction, and potential future performance in the pharmaceutical sector.

Risk Assessment

Risk Level: low — Jazz Pharmaceuticals plc shows low risk based on this filing. The filing is a standard quarterly report (10-Q) and does not contain unusual or high-risk disclosures.

Analyst Insight

Monitor future filings for detailed financial results and strategic updates from Jazz Pharmaceuticals plc.

Key Numbers

• 2024-03-31 — Period of Report (Conformed Period of Report)
• 2024-05-02 — Filing Date (Filed as of Date)
• 2024-01-01 — Quarter Start Date (Reporting period start date)
• 2024-03-31 — Quarter End Date (Reporting period end date)

Key Players & Entities

• Jazz Pharmaceuticals plc (company) — Filer
• 0001232524 (company) — Central Index Key
• 2834 (regulator) — Standard Industrial Classification
• L2 (regulator) — State of Incorporation
• 001-33500 (regulator) — SEC File Number
• 24905326 (regulator) — Film Number
• 353-1-634-7800 (dollar_amount) — Business Phone

FAQ

Industry Context

Jazz Pharmaceuticals plc operates within the pharmaceutical preparations industry, focusing on the development and commercialization of therapies.

Regulatory Implications

The company is subject to standard SEC regulations for public companies, including the requirement to file quarterly reports (10-Q).

What Investors Should Do

1. Review the full 10-Q filing for detailed financial statements and management discussion.
2. Analyze revenue segments and growth trends once available in subsequent filings or press releases.
3. Monitor any disclosures regarding product development, regulatory approvals, or market performance.

Key Dates

• 2024-05-02: 10-Q Filing — Filing of the quarterly report for the period ending March 31, 2024.

Year-Over-Year Comparison

This is the initial 10-Q filing for the fiscal year 2024, following the 2023 annual report.

Key Financial Figures

• $0.0001 — istered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Market

Filing Documents

• jazz-20240331.htm (10-Q) — 1351KB
• jazzq12024ex101.htm (EX-10.1) — 23KB
• jazzq12024ex102.htm (EX-10.2) — 26KB
• jazzq12024ex311.htm (EX-31.1) — 10KB
• jazzq12024ex312.htm (EX-31.2) — 10KB
• jazzq12024ex321.htm (EX-32.1) — 7KB
• 0001232524-24-000033.txt (&nbsp;) — 7847KB
• jazz-20240331.xsd (EX-101.SCH) — 53KB
• jazz-20240331_cal.xml (EX-101.CAL) — 99KB
• jazz-20240331_def.xml (EX-101.DEF) — 285KB
• jazz-20240331_lab.xml (EX-101.LAB) — 674KB
• jazz-20240331_pre.xml (EX-101.PRE) — 486KB
• jazz-20240331_htm.xml (XML) — 1176KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets – March 31, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Income (Loss) – Three Months Ended March 3 1 , 202 4 and 20 23 4 Condensed Consolidated Statements of Comprehensive Income (Loss) – Three Months Ended March 3 1 , 202 4 and 20 23 5 Condensed Consolidated Statements of Shareholders' Equity – Three Months Ended March 3 1 , 202 4 and 20 23 6 Condensed Consolidated Statements of Cash Flows – Three Months Ended March 3 1 , 202 4 and 20 23 7 Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 30

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 47

Controls and Procedures

Item 4. Controls and Procedures 47

– OTHER INFORMATION

PART II – OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 48

Risk Factors

Item 1A. Risk Factors 48

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 50

Other Information

Item 5. Other Information 50

Exhibits

Item 6. Exhibits 51

SIGNATURES

SIGNATURES 52 We own or have rights to various copyrights, trademarks, and trade names used in our business in the U.S. and/or other countries, including the following: Jazz Pharmaceuticals , Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Epidyolex (the trade name in Europe and other countries outside the U.S. for Epidiolex), Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Enrylaze (the trade name in Europe and other countries outside the U.S. and Canada for Rylaze), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium), Defitelio (defibrotide), Vyxeos (daunorubicin and cytarabine) liposome for injection, Vyxeos liposomal 44 mg/100 mg powder for concentrate for solution for infusion, CombiPlex and Sativex (nabiximols) oral solution. This Quarterly Report on Form 10-Q also includes trademarks, service marks and trade names of other companies. Trademarks, service marks and trade names appearing in this Quarterly Report on Form 10Q are the property of their respective owners. 2 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements JAZZ PHARMACEUTICALS PLC CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) March 31, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 1,443,385 $ 1,506,310 Investments 375,000 120,000 Accounts receivable, net of allowances 707,095 705,794 Inventories 577,321 597,039 Prepaid expenses 122,562 185,476 Other current assets 314,535 320,809 Total current assets 3,539,898 3,435,428 Property, plant and equipment, net 166,236 169,646 Operating lease assets 61,637 65,340 Intangible assets, net 5,235,496 5,418,039 Goodwill 1,739,495 1,753,130 Deferred tax assets, net 507,749 477,834 Deferred financing costs 5,784 6,478 Other non-current assets 70,780 67,464 Total assets $ 11,327,075 $ 11,393,359 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 80,976 $ 102,750 Accrued liabilities 826,530 793,914 Current portion of long-term debt 605,375 604,954 Income taxes payable 49,325 35,074 Total current liabilities 1,562,206 1,536,692 Long-term debt, less current portion 5,105,111 5,107,988 Operating lease liabilities, less current portion 56,158 59,225 Deferred tax liabilities, net 809,714 847,706 Other non-current liabilities 97,425 104,751 Commitments and contingencies (Note 9) Shareholders' equity: Ordinary shares 6 6 Non-voting euro deferred shares 55 55 Capital redemption reserve 473 473 Additional paid-in capital 3,714,283 3,699,954 Accumulated other comprehensive loss ( 882,394 ) ( 842,147 ) Retained earnings 864,038 878,656 Total shareholders' equity 3,696,461 3,736,997 Total liabilities and shareholders' equity $ 11,327,075 $ 11,393,359 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents JAZZ PHARMACEUTICALS PLC CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) (In thousands, except per share amounts) (Unaudited) Three Months Ended March 31, 2024 2023 Re

View Full Filing

View this 10-Q filing on SEC EDGAR